Presentation

21

May, 2018

The c4c project has been approved

 

We are delighted to announce the launch of the c4c project.
This heralds a new public-private partnership to improve clinical trial infrastructure to facilitate the development of new drugs for children in Europe.

READ MORE

1

Mar, 2017

ZIKAction

 

Happy to announce our ZIKAction project website is now live!

Watch this space…

READ MORE

14

Jul, 2015

Early antiretroviral therapy in children perinatally infected with HIV: a unique opportunity to implement immunotherapeutic approaches to prolong viral remission

 

Authors: Klein N, Palma P, Luzuriaga K, et al. Published in: Lancet Infect Dis. 2015;15(9):1108-1114. Abstract: From the use of antiretroviral therapy to prevent mother-to-child transmission to the possibility of HIV cure hinted at by the Mississippi baby experience, paediatric HIV infection has been pivotal to our understanding of HIV pathogenesis and management. Daily medication and indefinite antiretroviral therapy is recommended for children infected with HIV. Maintenance of life-long adherence is difficult and the incidence of triple-class virological failure after initiation of antiretroviral therapy increases with time. This challenge shows the urgent need to define novel strategies to provide long-term viral suppression that will allow safe interruption of antiretroviral therapy without viral rebound and any associated complications. HIV-infected babies treated within […]

READ MORE

23

Sep, 2014

Successful private-public funding of paediatric medicines research: lessons from the EU programme to fund research into off-patent medicines

 

Authors: Ruggieri L., Giannuzzi V., Baiardi P., Bonifazi F., Davies E.H., Giaquinto C. , Bonifazi D., Felisi M., Chiron C., Pressler R., Rabe H., Whitaker M.J., Neubert A., Jacqz-Aigrain E., Eichler I., Turner M.A., Ceci A; GRiP Consortium.

Published in: Eur J Pediatr. 2015, 174: 481-91.

Abstract: The European Paediatric Regulation mandated the European Commission to fund research on off-patent medicines with demonstrated therapeutic interest for children. Responding to this mandate, five FP7 pr

READ MORE